Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 4
4 · Boundless Bio, Inc. · Filed Apr 2, 2024
Insider Transaction Report
Form 4
Transactions
- Conversion
Series C Preferred Stock
2024-04-02−7,142,857→ 0 total→ Common Stock (366,300 underlying) - Conversion
Series B Preferred Stock
2024-04-02−3,703,704→ 0 total→ Common Stock (189,933 underlying) - Conversion
Common Stock
2024-04-02+189,933→ 189,933 total - Conversion
Common Stock
2024-04-02+366,300→ 556,233 total
Footnotes (2)
- [F1]On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date.
- [F2]On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date.